|
|
|
|
Mental Health Impacts of Climate Change: Educational Toolkit
May 12, 2022
 |
Emerging research suggests that climate change will increase the prevalence of posttraumatic stress disorder, depression, anxiety, psychotic disorders, and suicide. An educational toolkit has been developed to empower students to think critically about structural inequalities that affect them and challenge the assumption that they do not have the capacity to overcome the sociopolitical issues that affect them... |
|
 Continue reading (Members only)
|
|
FDA Authorizes Marketing for New Test to Improve Diagnosis of Alzheimer’s Disease
May 9, 2022
 |
The U.S. Food and Drug Administration (FDA) approved marketing authorizationnfor anst in vitro diagnostic test for the early detection of amyloid plaques, one of the pathological hallmarks associated with Alzheimer's adises. The test is the first FDA-authorized in vitro diagnostic test in the U.S. to aid in the assessment of Alzheimer’s disease and other causes of cognitive decline... |
|
Continue reading (Members only)
|
|
Non-Invasive Brain Stimulation For Smoking Cessation
May 4, 2022
 |
A recent review and meta-analysis of randomized controlled trials of non-invasive brain stimulation for the treatment of tobacco use disorder found that non-invasive brain stimulation may improve smoking abstinence rates for up to 6 months after smoking cessation compared to control. Current smoking cessation rates with no medical intervention are approximately... |
|
Continue reading (Members only)
|
|
FDA Approves Nonstimulant Option For Adults With ADHD
April 29, 2022
|
The U.S. Food and Drug Administration approved an expanded indication for viloxazine extended-release capsules for the treatment of attention deficit hyperactivity disorder in adult patients aged 18 and older, making it the first novel, nonstimulant option for adults with ADHD in 20 years. ... |
|
Continue reading
|
|
|
|
|
|
|
|
Vortioxetine in Patients with Major Depressive and Alcohol Use Disorders
April 17, 2022
 |
Major depressive disorder (MDD) is often found comorbid with alcohol use disorder (AUD) and patients with MDD+AUD often have a worsened illness and prognosis. Response of MDD+AUD to classic antidepressants, including selective serotonin reuptake inhibitors (SSRIs), norepinephrine serotonin reuptake inhibitors (SNRIs) and tricyclic antidepressants (TCAs) is often unsatisfactory. In this study... |
|
Continue reading (Members only)
|
|